IIROC Trade Resumption - AVBT

Trading resumes in:

Company: Avisa Diagnostics Inc. (formerly FogChain Corp.)

CSE Symbol: AVBT (formerly FOG.X)

Resumption (ET): 9:30 AM 5/18/2021

IIROC can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. IIROC is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada .

SOURCE Investment Industry Regulatory Organization of Canada (IIROC)

Cision View original content: https://www.newswire.ca/en/releases/archive/May2021/17/c1923.html

News Provided by Canada Newswire via QuoteMedia

pharmaceutical-investingcse-fog-x
The Conversation (0)

FogChain

FogChain Corp operates as a software as a service company. It provides a next-generation platform that seamlessly integrates application development and deployment that leverages a high-performance Fog based computing network to drive scale, and connects with the unique and ground-up built RadJav Blockchain. It operates in two segments namely Project development and Support and maintenance.

FogChain Corp operates as a software as a service company. It provides a next-generation platform that seamlessly integrates application development and deployment that leverages a high-performance Fog based computing network to drive scale, and connects with the unique and ground-up built RadJav Blockchain. It operates in two segments namely Project development and Support and maintenance. Keep Reading...
Scientists examining a sample under a microscope in a lab setting.

Gilead to Acquire Arcellx in US$7.8 Billion Bet on Cancer Therapy

Gilead Sciences (NASDAQ:GILD) announced plans to acquire cancer immunotherapy partner Arcellx (NASDAQ:ACLX) in a deal worth up to US$7.8 billion, moving to take full control of their jointly developed multiple myeloma therapy anito-cel as it seeks to expand its oncology pipeline.The agreement,... Keep Reading...
InMed Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update

InMed Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update

InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical drug development company focused on developing a pipeline of proprietary small-molecule drug candidates for diseases with high unmet medical needs, today reports financial results for its second quarter of... Keep Reading...
Pill labeled "GLP-1" on a $100 bill background.

As GLP-1 Brands Go Prime Time, Regulators Flag Growing Illicit Market

At Super Bowl LX, companies behind blockbuster GLP-1 medications spent tens of millions of dollars to court a mass audience. But as brand-name makers and telehealth platforms race to normalize and expand access, regulators on both sides are warning of a parallel surge in counterfeit, compounded,... Keep Reading...
Solvonis Therapeutics

Expansion of SVN-015 into Depression Following Positive Preclinical Data

Demonstrates antidepressant-like activity benchmarked against fluoxetine (Prozac®), supporting potential in patients with inadequate SSRI response

Solvonis Therapeutics plc (LSE: SVNS), an emerging biopharmaceutical company developing novel medicines for high-burden central nervous system ("CNS") disorders, announces the expansion of its investigational compound SVN-015 into the treatment of depression, supported by preclinical data... Keep Reading...
Blank pill bottle spilling a variety of pharmaceutical pills and capsules.

5 Biggest Pharmaceutical ETFs for Investors in 2026

Experienced and novice investors alike may want to consider pharmaceutical exchange-traded funds (ETFs) as a way to gain exposure to the top pharma companies and the pharma market as a whole. Like all ETFs, pharmaceutical ETFs are a good option for those who want to trade a set of assets in the... Keep Reading...
InMed Announces Results of 2025 Annual General and Special Meeting

InMed Announces Results of 2025 Annual General and Special Meeting

InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today confirmed that, at its annual general and special meeting of shareholders... Keep Reading...

Latest News

Interactive Chart

Latest Press Releases

Eagle Energy Metals and Spring Valley Acquisition Corp. II Announce Closing of Business Combination

Toronto to Host Global Mineral Sector for PDAC 2026, March 1 – 4

Fathom Announces Completion of Gochager Lake Winter Trail and Expected Start of Winter Drill Program

Iyan Deposit Delivers Further Significant Graphite Intercepts from Surface in the Final Release of Assays

Related News

uranium investing

Eagle Energy Metals and Spring Valley Acquisition Corp. II Announce Closing of Business Combination

gold investing

Toronto to Host Global Mineral Sector for PDAC 2026, March 1 – 4

nickel investing

Fathom Announces Completion of Gochager Lake Winter Trail and Expected Start of Winter Drill Program

graphite investing

Iyan Deposit Delivers Further Significant Graphite Intercepts from Surface in the Final Release of Assays

rare earth investing

Application to Trade on OTCQB Market

base metals investing

Tartisan Nickel Corp. Intersects 3.0 Metres of 2.17% Ni, 1.45% Cu at The Kenbridge Nickel-Copper-Cobalt Project, Northwestern Ontario

gold investing

THE SIGNAL ARCHITECTURE: 5 Stocks Calibrating the 2026 Infrastructure Cycle